Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (61-70 of 339) with videos related to

Pageof 34
Sort By:
Leukemia & Lymphoma|April 25, 2009
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemiaThomas Schroeder, Akos Czibere, Fabian Zohren, et al.
British Journal of Haematology|November 5, 2011
Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantationRoland Fenk, Florian Neubauer, Ingmar Bruns, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?Annika Kasprzak, Jennifer Kaivers, Kathrin Nachtkamp, et al.
Haematologica|September 2, 2004
No increase in age-specific incidence of myelodysplastic syndromesUlrich Germing, Corinna Strupp, Andrea Kündgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2006
Myelodysplastic syndromes in patients younger than age 50Andrea Kuendgen, Corinna Strupp, Manuel Aivado, et al.
Annals of Hematology|September 11, 2013
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Haematologica|October 2, 2009
Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survivalAkos Czibere, Ingmar Bruns, Bärbel Junge, et al.
Leukemia Research|March 7, 2003
Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposalsCorinna Strupp, Norbert Gattermann, Aristoteles Giagounidis, et al.
Expert Review of Hematology|July 20, 2019
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromesGuido Kobbe, Thomas Schroeder, Christina Rautenberg, et al.
Annals of Hematology|March 18, 2009
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabineIsabel Möller, Sabine Blum, Norbert Gattermann, et al.
Pageof 34

Showing results (61-70 of 339) with videos related to

Sort By:
Pageof 34
Leukemia & Lymphoma|April 25, 2009
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemiaThomas Schroeder, Akos Czibere, Fabian Zohren, et al.
British Journal of Haematology|November 5, 2011
Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantationRoland Fenk, Florian Neubauer, Ingmar Bruns, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?Annika Kasprzak, Jennifer Kaivers, Kathrin Nachtkamp, et al.
Haematologica|September 2, 2004
No increase in age-specific incidence of myelodysplastic syndromesUlrich Germing, Corinna Strupp, Andrea Kündgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2006
Myelodysplastic syndromes in patients younger than age 50Andrea Kuendgen, Corinna Strupp, Manuel Aivado, et al.
Annals of Hematology|September 11, 2013
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Haematologica|October 2, 2009
Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survivalAkos Czibere, Ingmar Bruns, Bärbel Junge, et al.
Leukemia Research|March 7, 2003
Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposalsCorinna Strupp, Norbert Gattermann, Aristoteles Giagounidis, et al.
Expert Review of Hematology|July 20, 2019
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromesGuido Kobbe, Thomas Schroeder, Christina Rautenberg, et al.
Annals of Hematology|March 18, 2009
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabineIsabel Möller, Sabine Blum, Norbert Gattermann, et al.
Pageof 34